Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06073301 · ClinicalTrials.gov registry record · Phase 4
AFS Compared to AHC in Treatment of Necrotizing Fasciitis NF
A Phase 4 study of Necrotizing Fasciitis, sponsored by Kerecis.
- Active
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06073301 is a Phase 4 study of Necrotizing Fasciitis that is active but no longer recruiting, run by Kerecis. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06073301, a Phase 4 study of Necrotizing Fasciitis, is active but no longer recruiting, sponsored by Kerecis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Necrotizing Fasciitis (NF) is a potentially life-threatening soft tissue infection. This study is comparing acellular fish skin graft (AFS) to standard of care allograft (AHC) in the treatment of NF. The purpose of this study is to compare clinical outcomes and time until autograft take in patients that were treated with AHC or AFS prior to permanent autografting to treat NF.
Conditions Studied
Interventions
- DEVICE Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT)
- OTHER Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT)
Study Locations (1)
Georgia
- Joseph M. Still Research Foundation - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06073301
The ClinicalTrials.gov registry entry for NCT06073301 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kerecis, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Necrotizing Fasciitis appearing as the primary indexed condition, and to 2 interventions - of which Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT) is the first listed.
NCT06073301 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06073301 about?
NCT06073301 is a clinical study titled "AFS Compared to AHC in Treatment of Necrotizing Fasciitis NF". Necrotizing Fasciitis (NF) is a potentially life-threatening soft tissue infection. This study is comparing acellular fish skin graft (AFS) to standard of care allograft (AHC) in the treatment of NF. The purpose of this study is to compare clinical outcomes and time until autograft take in patients ...
What is the current status of trial NCT06073301?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2023-08-01. Estimated completion is 2025-12-01.
What conditions does trial NCT06073301 study?
This clinical trial studies the following conditions: Necrotizing Fasciitis.
What interventions are being tested in trial NCT06073301?
The interventions under investigation include: Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT) (DEVICE), Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT) (OTHER).
Who is sponsoring clinical trial NCT06073301?
This trial is sponsored by Kerecis, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06073301 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.